Product classification
Define whether the planned product fits FSMP, medical food or another regulated route before technical assumptions are locked.
FSMP · MEDICAL FOOD · CLINICAL NUTRITION
Olympia delivers routine premium FSMP, medical-food and clinical-nutrition programs with bespoke scope design across product, evidence, target market, regulatory pathway and technical execution.
Commercial route: fsmp_bespoke_scoping. No automatic price, SoW, feasibility commitment or Manufacturing Credit is issued before approved scoping.
Certified quality systems and audited legal evidence are published in our Legal Hub. FSMP and medical-nutrition work is a routine service category, not a manual exception path.
Initial scoping can cover hard capsules, softgels, powders/sachets, liquids and other delivery systems when project requirements, target-market rules and technical feasibility align.
End-to-end competence is delivered as a governed sequence: formulation architecture, evidence plan, documentation scope, manufacturing fit and scale-up readiness under one named programme owner.
Each programme is scoped against six decision risks before commercial or technical commitments are issued.
Define whether the planned product fits FSMP, medical food or another regulated route before technical assumptions are locked.
Set what clinical and scientific evidence is required for the intended claims and what remains hypothesis until verified.
Map the named launch markets and corresponding documentation path instead of assuming one regulation serves every jurisdiction.
Confirm dosage form fit, ingredient constraints and process requirements before selecting a manufacturing route.
Align dossier scope, analytical controls and quality evidence with the approved pathway and contract boundaries.
Define what can scale, what must be revalidated and which dependencies remain client-side before production conversion.
The FSMP route remains routinely available and bespoke by design: individual scientific scope, individual commercial scope and governed delivery boundaries.
INITIATE R&D DUE DILIGENCERELATED INTELLIGENCE
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.